Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04817735
Other study ID # PI-2021-01
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 1, 2021
Est. completion date March 30, 2023

Study information

Verified date May 2022
Source University of Pisa
Contact Anna Sonia Petronio, M.D.
Phone +39050995326
Email as.petronio@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The CASPER study is a prospective, international, multicenter registry which aims to evaluate the use of an algorithm for choosing the size of the prosthesis to be implanted in patients with bicuspid aortic stenosis type I treated by TAVI with Evolut® Pro prostheses (23 -26-29) and Evolut® R 34.


Description:

STUDY DESIGN This is an Investigator initiated, international, multicenter, prospective registry, enrolling 100 consecutive BAV patients who will undergo TAVI with the Evolut R/Pro (23-26-29)/Evolut R 34THV. Enrollment will be without limitation for each center (competitive enrollment). The indication for TAVI will be based on each local Heart Team decision. As per local institution's regulatory policy, each patient will provide a written informed consent for the TAVI procedure, anonymous data collection and analysis. Each center will use its own consent template. All data will be collected in an electronic clinical report form (eCRF). STUDY POPULATION Population All consecutive patients diagnosed with type 0 or type 1 bicuspid aortic valve stenosis or steno-insufficiency disease, undergoing transcatheter aortic valve implantation, as per local standard of care. CASPER algorithm The sizing of the THV will be performed according to the proposed algorithm. First step ("calcium impact"): subtract 1 mm in patients with aortic calcium volume ≥300 mm3 (i.e. ≥ Class I); no subtraction in patients with aortic calcium volume <300 mm3 (i.e. Class 0). Second step ("raphe impact"): subtract 1 mm if the raphe length is ≥50% of the perimeter derived mean annulus diameter Further 0.5 mm will be subtracted if a high burden of calcium is distributed predominantly on the raphe site. In case of bicuspid Type 0 the second step should be skipped. Transcatheter Aortic Valve Implantation Procedure TAVI will be performed according to the local standards of care. Balloon valvuloplastywill be performed to prepare for TAVI deployment, at operator's discretion. Balloon size should not exceed the minimal diameter of the aortic annulus at baseline. TAVI deployment will be performed as the current best practices. All Centers will be encouraged to implant THV according to the two cusp alignment technique. If necessary, post dilatation will be performed, based on the final hemodynamics and aortic regurgitation assessment. The postdilatation will be performed according to the calcium burden with a balloon size diameter equal to the minor annulus diameter or to the mean diameter. Post-procedural MSCT scan The post-procedural MSCT scan must be performed between 2 and 30 days after the index procedure. Post implant measurements of THV dimensions (perimeter and area) will be obtained at inflow level, raphe level, and stent waist level (defined as the smallest dimension observed at any plane of the implanted prosthesis). If the raphe level corresponds to the stent waist level, only one measurement will be reported. Eccentricity index will be calculated for each level. Eccentricity will be defined as 1-(minimal diameter/maximal diameter) and will be calculated both at the inflow and at the narrowest level. The post-procedural raphe length (defined as the longest measurable dimension of the structure) will be measured at the same level of pre-procedural MSCT. The ratio between the pre and post-procedure raphe length will be calculated for the assessment of raphe shortening. Strut separation data will be acquired (maximal strut distance, mean strut distance, strut eccentricity index, i.e. maximal-minimal strut separation). The stent strut spaces will be measured separately at the inflow level, with the first stent strut defined as the strut closest to the commissure between the non-coronary and right coronary sinuses. The subsequent struts will be numbered clockwise in an ascending order (1-15 for the Evolut THV).


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date March 30, 2023
Est. primary completion date March 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age =18 years. 2. NYHA=2 and/or syncope and/or angina. 3. Patient judged by the Heart Team as indicated for TAVI. 4. Anatomical suitability for transfemoral or any alternative access TAVI, based on MSCT assessment and local expertise and preference. 5. Estimated life expectancy>1 year. Exclusion Criteria: 1. Age <18 years 2. Estimated life expectancy<1 year 3. Pure aortic regurgitation. 4. LVEF<20% 5. No baseline MSCT evaluation.

Study Design


Intervention

Procedure:
TAVI
TAVI sizing with dedicated algorithm

Locations

Country Name City State
Italy Azienda Ospedaliero Universitaria Pisana Pisa

Sponsors (1)

Lead Sponsor Collaborator
University of Pisa

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy of the CASPER algorithm The objective of the study is to validate the CASPER algorithm in a prospective cohort using a self-expandable THV, in order to assess the safety and efficacy of bicuspid aortic valve sizing based on calcium burden and raphe length. 1 year
Secondary Safety of the CASPER algorithm To assess valve performance in terms of prosthesis mismatch and valve dysfunction (clinical features), and post-procedural CT assessment of the prosthesis behavior. 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT01390181 - The Effect of Losartan in Bicuspid Aortic Valve Patients N/A
Enrolling by invitation NCT06212050 - Feasibility, Safety, and Effectiveness of the ACURATE neo2 Transcatheter Heart Valve for Severe Bicuspid Aortic Stenosis
Active, not recruiting NCT03635424 - Medtronic Transcatheter Aortic Valve Replacement (TAVR) Low Risk Bicuspid Study N/A
Recruiting NCT06153407 - Genetic Test Based Risk Prediction of Early Calcific Aortic Valve Disease in Patients With Bicuspid Aortic Valve
Active, not recruiting NCT03474159 - Evaluation of Aortic Stiffness as a Prognostic Indicator of Aortic Dilatation in Patients With Bicuspid Aortic Valve by Multimodal Imaging N/A
Not yet recruiting NCT06375590 - NavIIcusp: Bicuspid Aortic Valve Stenosis With Navitor Platform International Experience
Recruiting NCT05739253 - Changes of Ascending Aortic Diameter in Patients Undergoing Transcatheter Aortic Valve Replacement
Completed NCT01823432 - Genetic Risks for Bicuspid Aortic Valve Disease
Completed NCT02679261 - Evaluating the Effectiveness of Atorvastatin on the Progression of Aortic Dilatation and Valvular Degeneration in Patients With Bicuspid Aortic Valve Phase 3
Completed NCT01920815 - Bicuspid Valve Aortopathy Feasibility Study
Recruiting NCT02899624 - Whole Exome Sequencing in Bicuspid Aortic Valve Patients N/A
Recruiting NCT05708118 - Progression of Ascending Aorta Diameters in Bicuspid Aortic Valve After Transcatheter or Surgical Replacement.
Recruiting NCT03495050 - BIVOLUTX: Bicuspid Aortic Stenosis With Evolut Platform International Experience.
Completed NCT01760668 - Aortopathy in Persons With Bicuspid Aortic Valve, Turner and Marfan Syndrome N/A
Not yet recruiting NCT05711693 - Measurement of Heart-carotid Pulse Wave Velocity (hcPWV) by Laser Doppler Vibrometry (LDV) N/A
Completed NCT05836363 - Fate at Long-term of Mild to Moderate Bicuspid Aortic Valve Disease Left Untreated at the Time of Supracoronary Ascending Aorta Replacement
Completed NCT02283970 - Investigation of Patients With BAV Requiring Valve and/or Aortic Repair (GISSI Outliers VAR)
Active, not recruiting NCT01026571 - Identification of Genetic Causes of Bicuspid Aortic Valve Disease
Completed NCT00412386 - Abnormal 3-D MRI Flow Patterns in Adolescents Patients With Bicuspid Aortic Valve N/A
Recruiting NCT03440697 - Pathogenetic Basis of Aortopathy and Aortic Valve Disease